real-time news and commentary for investors
Wednesday, Mar 13
The FDA has approved Navidea Biopharmaceutical's (NAVB -7.4%) Lymphoseek injection, a...
The FDA has approved Navidea Biopharmaceutical's (NAVB -7.4%) Lymphoseek injection, a radioactive imaging agent meant to help doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove the lymph nodes. The drug, which is the first new lymph-node mapping agent approved in more than 30 years, is injected into the tumor area and later, using a hand-held radiation detector, identifies lymph nodes that have taken up Lymphoseek.